Walking ability in adults with severe hemophilia: A cross-sectional study [0.03%]
重度甲型血友病成人患者步行能力的横断面研究
Malika Jhandai,Dimple Choudhry,Sudhir Kumar Atri et al.
Malika Jhandai et al.
A lack of factor VIII (FVIII) or factor IX (FIX) results in hemophilia, a blood-clotting illness. The mode of inheritance is chromosome X-linked and recessive. The primary symptom of severe hemophilia is spontaneous and recurrent bleeding i...
Wolfgang P Rennert,Jenna Smith M,Katie A Cormier et al.
Wolfgang P Rennert et al.
Supportive care needs for hematopoietic stem cell recipients have been studied. Less is known about the care needs of stem cell donors. Care challenges arise at donor selection, preparation for the donation, the donation procedure and the i...
The Role of Vertebral Augmentation Procedures in the Management of Multiple Myeloma [0.03%]
多发性骨髓瘤治疗中椎体成型术的作用
Nishanth Thalambedu,Mudassar Kamran,Samer Al-Hadidi
Nishanth Thalambedu
Approximately 90% of patients with multiple myeloma experience significant pain from osseous involvement during their lifetime. Untreated osseous involvement results in vertebral compression fractures, leading to negative consequences for q...
Early de-escalation of antibiotic therapy in hospitalized cellular therapy adult patients with febrile neutropenia [0.03%]
有关发热性中性粒细胞减少成人细胞治疗住院患者抗生素降阶梯治疗的时机探索研究
Mariana Lucena,Kelly J Gaffney,Theresa Urban et al.
Mariana Lucena et al.
Febrile neutropenia (FN) is an oncologic emergency frequently encountered in hematopoietic cell transplant (HCT) and chimeric antigen receptor (CAR) T-cell therapy patients, which requires immediate initiation of broad-spectrum antibiotics....
Incidence and Risk of Secondary Malignancy in Patients with Waldenström Macroglobulinemia: A Population-Based Analysis [0.03%]
华氏巨球蛋白血病继发恶性肿瘤的发病及风险分析：基于人口的队列研究
Mohammad Ebad Ur Rehman,Maha Hameed,Zunairah Shah et al.
Mohammad Ebad Ur Rehman et al.
Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma which may predispose individuals to development of secondary malignancies (SMs). The Surveillance, Epidemiology, and End Results (SEER) database is a comprehensive reg...
The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going? [0.03%]
嵌合抗原受体(CAR)T细胞疗法在儿科患者中的应用：我们从哪里来？我们现在在哪里？我们将去哪里？
Tristan Knight E,Olalekan Oluwole,Carrie Kitko
Tristan Knight E
CD19-directed Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL). Somewhat uniquely among oncologic clinical trials, early clinical development occurr...
Epidemiology, Treatment Trends, and Outcomes of Multiple Myeloma in the Middle East and Africa: A Systematic Review [0.03%]
中东和非洲多发性骨髓瘤的流行病学、治疗趋势及结局：系统综述
Mervat Mattar,Ali Bazarbachi,Omar Abduljalil et al.
Mervat Mattar et al.
Background: Globally, multiple myeloma (MM) ranks 24th among the most common cancers. The Middle East and Africa are affected by an increasing trend in MM incidence, owing to several underlying factors. This systematic re...
Prevention and management of acute toxicities from conditioning regimens during hematopoietic stem cell transplantation [0.03%]
造血干细胞移植时 Conditioning 方案相关急性毒副反应的防治
Jana Sawyer,Taylor Elliott,Lindsay Orton et al.
Jana Sawyer et al.
Hematopoietic stem cell transplantation (HSCT) remains the only curative option for several hematological malignancies. Its use has continued to grow, with an estimated 23,500 transplants performed annually in the United States alone. The a...
Outcomes of Autologous stem cell transplantation in patients with primary refractory Diffuse Large B-cell lymphoma who demonstrate chemosensitivity to salvage chemotherapy [0.03%]
自体干细胞移植治疗对原发耐药及解救化疗敏感的大B细胞淋巴瘤患者的疗效分析
M Shahzad Rauf,Irfan Maghfoor,Muhammad Aseafan et al.
M Shahzad Rauf et al.
Rituximab with anthracycline-based combination frontline chemoimmunotherapy can cure 50-60% of patients with diffuse large B-cell lymphoma (DLBCL). However, studies on the outcomes of patients with DLBCL who experience partial response (PR)...
Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy [0.03%]
嵌合抗原受体T细胞(CAR-T)治疗相关的感染并发症管理
Nausheen Ahmed,Olalekan Oluwole,Zahra Mahmoudjafari et al.
Nausheen Ahmed et al.
Chimeric antigen receptor T-cell (CAR T-cell) therapy has changed the paradigm of management of non-Hodgkin's lymphoma (NHL) and Multiple Myeloma. Infection complications have emerged as a concern that can arise in the setting of therapy an...